| scholarly article | Q13442814 |
| P50 | author | Weizhi Ji | Q44845569 |
| P2093 | author name string | Yongchang Chen | |
| Hong Wang | |||
| Xiangyu Guo | |||
| Xiao-Jiang Li | |||
| Shihua Li | |||
| Yu Kang | |||
| Yinghui Zheng | |||
| Shang-Hsun Yang | |||
| Chenyang Si | |||
| Yuyu Niu | |||
| Ruxiao Xing | |||
| Weili Yang | |||
| Zhuchi Tu | |||
| Xiuqiong Pu | |||
| P2860 | cites work | Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 |
| X chromosome-linked muscular dystrophy (mdx) in the mouse | Q28589078 | ||
| One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering | Q29547524 | ||
| High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells | Q29616045 | ||
| Dystrophin: the protein product of the Duchenne muscular dystrophy locus | Q29618077 | ||
| Genetic engineering of human pluripotent cells using TALE nucleases | Q29619830 | ||
| Timely translation during the mouse oocyte-to-embryo transition. | Q30898601 | ||
| TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys | Q33625156 | ||
| Dystrophin and mutations: one gene, several proteins, multiple phenotypes | Q34278933 | ||
| Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications | Q34497055 | ||
| The formation of skeletal muscle: from somite to limb | Q35066903 | ||
| Feline muscular dystrophy with dystrophin deficiency | Q35817354 | ||
| The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies | Q37383091 | ||
| The paradox of muscle hypertrophy in muscular dystrophy. | Q37975319 | ||
| The medical genetics of dystrophinopathies: molecular genetic diagnosis and its impact on clinical practice | Q38057078 | ||
| Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. | Q39028341 | ||
| Duchenne muscular dystrophy: Pathogenetic aspects and genetic prevention | Q40170529 | ||
| Generation of a monkey with MECP2 mutations by TALEN-based gene targeting | Q41458178 | ||
| Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. | Q51761621 | ||
| The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy | Q59051261 | ||
| The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs | Q59051983 | ||
| An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy | Q59416437 | ||
| Dystrophin deficiency causes lethal muscle hypertrophy in cats | Q68020670 | ||
| Dystrophy-like myopathy in the cat | Q69549711 | ||
| Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study | Q69943407 | ||
| Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse | Q70039598 | ||
| The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation | Q70054992 | ||
| Muscle development in mdx mutant mice | Q70804155 | ||
| The muscular dystrophies | Q77731754 | ||
| P4510 | describes a project that uses | CRISPR-Cas method | Q17310682 |
| P433 | issue | 13 | |
| P921 | main subject | CRISPR | Q412563 |
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| P304 | page(s) | 3764-3774 | |
| P577 | publication date | 2015-04-09 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9 | |
| P478 | volume | 24 |
| Q42546298 | A Perspective on the State of Genome Editing |
| Q52430570 | An efficient platform for generating somatic point mutations with germline transmission in the zebrafish by CRISPR/Cas9-mediated gene editing. |
| Q64929729 | Anephrogenic phenotype induced by SALL1 gene knockout in pigs. |
| Q34671188 | Application of CRISPR/Cas9 for biomedical discoveries |
| Q37165527 | Application of the genome editing tool CRISPR/Cas9 in non-human primates |
| Q34539796 | Applications of CRISPR technologies in research and beyond |
| Q93376356 | Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy |
| Q91866605 | Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy |
| Q91970445 | Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects |
| Q38756882 | Assisted reproductive technologies in the common marmoset: an integral species for developing nonhuman primate models of human diseases |
| Q87985442 | CRISPR Editing in Biological and Biomedical Investigation |
| Q38645581 | CRISPR Editing in Biological and Biomedical Investigation. |
| Q90663059 | CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy |
| Q97535454 | CRISPR-based functional genomics for neurological disease |
| Q57253681 | CRISPR-mediated genome editing and human diseases |
| Q60954918 | CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus |
| Q57493121 | CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering |
| Q89873570 | CRISPR/Cas9-mediated genome editing: From basic research to translational medicine |
| Q26747564 | CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases |
| Q26799640 | CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases |
| Q50196918 | CRISPR: Established Editor of Human Embryos? |
| Q39051110 | Cornerstones of CRISPR-Cas in drug discovery and therapy |
| Q42094546 | Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System. |
| Q38682882 | Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery |
| Q38696285 | Current Progress in Therapeutic Gene Editing for Monogenic Diseases |
| Q28078561 | Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease |
| Q47704855 | Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. |
| Q89448668 | Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine |
| Q37227736 | Efficient Production of Gene-Modified Mice using Staphylococcus aureus Cas9. |
| Q26785547 | Engineering large animal models of human disease |
| Q98178387 | Generation of Gene-Knockout Mongolian Gerbils via CRISPR/Cas9 System |
| Q88016594 | Generation of genetically modified mice using CRISPR/Cas9 and haploid embryonic stem cell systems |
| Q47868055 | Generation of knock-in cynomolgus monkey via CRISPR/Cas9 editing |
| Q99710875 | Generation of myostatin edited horse embryos using CRISPR/Cas9 technology and somatic cell nuclear transfer |
| Q36830387 | Generation of transgenic cynomolgus monkeys that express green fluorescent protein throughout the whole body |
| Q33729585 | Genome Editing and Muscle Stem Cells as a Therapeutic Tool for Muscular Dystrophies |
| Q38817680 | Genome editing in nonhuman primates: approach to generating human disease models |
| Q90220217 | Genome editing methods in animal models |
| Q101051155 | Genome editing of CCR5 by CRISPR-Cas9 in Mauritian cynomolgus macaque embryos |
| Q38901709 | Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases |
| Q37417137 | Genome editing: progress and challenges for medical applications |
| Q41928233 | Genome engineering: a new approach to gene therapy for neuromuscular disorders. |
| Q49478512 | Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease |
| Q37623660 | Germ line genome editing in clinics: the approaches, objectives and global society |
| Q61447926 | Homologous recombination-mediated targeted integration in monkey embryos using TALE nucleases |
| Q38702939 | Homology-mediated end joining-based targeted integration using CRISPR/Cas9. |
| Q64276851 | Local transgene expression and whole-body transgenesis to model brain diseases in nonhuman primate |
| Q52430996 | Modeling autism in non-human primates: Opportunities and challenges. |
| Q51357966 | Monkey kingdom. |
| Q57802324 | Mosaicism in CRISPR/Cas9-mediated Genome editing |
| Q88540277 | Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing |
| Q52426276 | New models: Gene-editing boom means changing landscape for primate work. |
| Q57174413 | No off-target mutations in functional genome regions of a CRISPR/Cas9-generated monkey model of muscular dystrophy |
| Q37714590 | Non-human Primate Models for Brain Disorders - Towards Genetic Manipulations via Innovative Technology |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q47562567 | Nonhuman Primates and Translational Research: Progress, Opportunities, and Challenges |
| Q41791974 | Nonhuman Primates: A Vital Model for Basic and Applied Research on Female Reproduction, Prenatal Development, and Women's Health |
| Q53422584 | Of Men and Mice: Modeling the Fragile X Syndrome. |
| Q41071025 | One-step generation of complete gene knockout mice and monkeys by CRISPR/Cas9-mediated gene editing with multiple sgRNAs |
| Q38826903 | Opportunities and challenges in modeling human brain disorders in transgenic primates |
| Q60912966 | Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech |
| Q34497471 | Progress and prospects of gene therapy clinical trials for the muscular dystrophies. |
| Q37622753 | Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos |
| Q37021623 | Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy |
| Q38819336 | Quantitative assessment of timing, efficiency, specificity and genetic mosaicism of CRISPR/Cas9-mediated gene editing of hemoglobin beta gene in rhesus monkey embryos |
| Q40355957 | Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers. |
| Q36900663 | Sites of retroviral DNA integration: From basic research to clinical applications |
| Q90107967 | Studying human and nonhuman primate evolutionary biology with powerful in vitro and in vivo functional genomics tools |
| Q38618881 | Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies |
| Q28080423 | Targeted genome editing in primate embryos |
| Q38836751 | The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models |
| Q57729296 | The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies |
| Q89617956 | The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations |
| Q36253010 | The societal opportunities and challenges of genome editing |
| Q39230334 | Use of CRISPR/Cas9 to model brain diseases |
| Q50226687 | Vesicles Cytoplasmic Injection: An Efficient Technique to Produce Porcine Transgene-Expressing Embryos. |
| Q38564564 | Viral vector-mediated gene therapies |
| Q47152743 | Vitrification of Rhesus Macaque Mesenchymal Stem Cells and the Effects on Global Gene Expression. |
Search more.